Keyphrases
Acute Myeloid Leukemia
100%
Relapsed or Refractory Acute Myeloid Leukemia
28%
Acute Promyelocytic Leukemia
27%
Arsenic Trioxide
24%
Mammalian Target of Rapamycin (mTOR)
23%
Antileukemic Activity
22%
Relapsed or Refractory
20%
Leukemia
19%
Complete Remission
17%
Myelodysplastic Syndrome
16%
Newly Diagnosed
16%
Gilteritinib
15%
Chronic Myeloid Leukemia
15%
All-trans Retinoic Acid
13%
NCCN Guidelines
12%
FMS-like Tyrosine Kinase 3 (FLT3)
12%
Cytarabine
11%
FLT3 mutation
10%
Suppression Effect
10%
Overall Survival
10%
BCR-ABL
10%
Monotherapy
10%
Isocitrate Dehydrogenase 1 (IDH1)
8%
Induction Chemotherapy
8%
MTOR Inhibitor
8%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
8%
Regulatory Effect
7%
Phase 1 Study
7%
Venetoclax
7%
FLT3 Inhibitor
7%
Phosphorylation
7%
Leukemic Cells
7%
MTOR Complex 2 (mTORC2)
7%
Tyrosine Kinase Inhibitor
7%
Phase II Trial
7%
Chemotherapy
6%
Malignancy
6%
Mammalian Target of Rapamycin Pathway
6%
Leukemia Cells
6%
Confidence Interval
6%
Leukemia Patients
5%
Hypomethylating Agents
5%
Myeloid Neoplasms
5%
Inhibitory Effect
5%
Patients with Cancer
5%
Hematological Malignancies
5%
Adult Patients
5%
Consolidation Chemotherapy
5%
Phase II Study
5%
Interferon Signaling
5%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Myeloid Leukemia
91%
Promyelocytic Leukemia
26%
Remission
23%
Arsenite
21%
Arsenous Acid
21%
Chemotherapy
19%
Mammalian Target of Rapamycin
16%
Gilteritinib
16%
Cytarabine
15%
Retinoic Acid
14%
Chronic Myeloid Leukemia
12%
Leukemia
12%
Myelodysplastic Syndrome
11%
Overall Survival
11%
Diseases
10%
Protein Tyrosine Kinase Inhibitor
10%
Malignant Neoplasm
10%
Phosphotransferase
10%
Monotherapy
9%
Adverse Event
8%
Mammalian Target of Rapamycin Inhibitor
7%
Venetoclax
7%
Clinical Trial
7%
Pharmacokinetics
6%
Messenger RNA
6%
Azacitidine
5%
Ivosidenib
5%
S6 Kinase
5%
Medicine and Dentistry
Acute Myeloid Leukemia
79%
Acute Promyelocytic Leukemia
24%
Arsenic Trioxide
23%
Diseases
15%
Chronic Myelogenous Leukemia
14%
Myelodysplastic Syndrome
13%
Tretinoin
12%
Cytarabine
10%
Leukemia
9%
Neoplasm
9%
Overall Survival
8%
Malignant Neoplasm
7%
Oncology
7%
Mechanistic Target of Rapamycin
7%
Monotherapy
7%
Clinical Trial
7%
Leukemia Cell
6%
Phosphotransferase
6%
Arm
6%
Tyrosine-Kinase Inhibitor
6%
Adverse Event
5%
Precursor
5%
Targeted Therapy
5%
COVID-19
5%
Autophagy
5%